IDEAYA BIOSCIENCES INC (IDYA) Stock Price, Forecast & Analysis
NASDAQ:IDYA • US45166A1025
IDYA Key Statistics, Chart & Performance
The current stock price of IDYA is 31.52 USD. In the past month the price decreased by -14.88%. In the past year, price increased by 50.1%.
IDYA Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to IDYA. When comparing the yearly performance of all stocks, IDYA is one of the better performing stocks in the market, outperforming 83.36% of all stocks.
IDYA Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to IDYA. While IDYA has a great health rating, there are worries on its profitability.
IDYA Financial Highlights
Over the last trailing twelve months IDYA reported a non-GAAP Earnings per Share(EPS) of -1.86. The EPS increased by 20.17% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -13.52% | ||
| ROE | -14.67% | ||
| Debt/Equity | 0 |
IDYA Forecast & Estimates
25 analysts have analysed IDYA and the average price target is 50.94 USD. This implies a price increase of 61.61% is expected in the next year compared to the current price of 31.52.
For the next year, analysts expect an EPS growth of 56.82% and a revenue growth 4195.55% for IDYA
IDYA Ownership
IDYA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.67 | 390.397B | ||
| AMGN | AMGEN INC | 16.25 | 197.396B | ||
| GILD | GILEAD SCIENCES INC | 17.02 | 193.298B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.81 | 117.026B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.87 | 81.87B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 46.05 | 42.576B | ||
| INSM | INSMED INC | N/A | 31.656B | ||
| NTRA | NATERA INC | N/A | 29.322B | ||
| BIIB | BIOGEN INC | 12.85 | 28.06B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.16 | 20.49B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About IDYA
Company Profile
IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The company is headquartered in South San Francisco, California and currently employs 131 full-time employees. The company went IPO on 2019-05-23. The firm is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 / GSK959 (Werner Helicase), IDE161 (PARG), and IDE705 / GSK101 (Pol Theta Helicase). IDE196, a small-molecule protein kinase C (PKC) inhibitor, in combination with crizotinib, an investigational cMET inhibitor. IDE397 is its small-molecule methionine adenosyltransferase 2a (MAT2A) inhibitor. IDE275 (GSK959) Werner Helicase (WRN) inhibitor for patients having tumors with MSI-High. IDE161 (PARG) is a small-molecule poly (ADP-ribose) glycohydrolase, or PARG, inhibitor. IDE705 is a small-molecule inhibitor of Pol Theta Helicase, in combination with niraparib, the GSK small-molecule inhibitor of poly-(ADP-ribose) polymerase (PARP).
Company Info
IDEAYA BIOSCIENCES INC
7000 Shoreline Ct, Suite 350
South San Francisco CALIFORNIA 94080 US
CEO: Yujiro Hata
Employees: 131
Phone: 16504436209
IDEAYA BIOSCIENCES INC / IDYA FAQ
What does IDYA do?
IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The company is headquartered in South San Francisco, California and currently employs 131 full-time employees. The company went IPO on 2019-05-23. The firm is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 / GSK959 (Werner Helicase), IDE161 (PARG), and IDE705 / GSK101 (Pol Theta Helicase). IDE196, a small-molecule protein kinase C (PKC) inhibitor, in combination with crizotinib, an investigational cMET inhibitor. IDE397 is its small-molecule methionine adenosyltransferase 2a (MAT2A) inhibitor. IDE275 (GSK959) Werner Helicase (WRN) inhibitor for patients having tumors with MSI-High. IDE161 (PARG) is a small-molecule poly (ADP-ribose) glycohydrolase, or PARG, inhibitor. IDE705 is a small-molecule inhibitor of Pol Theta Helicase, in combination with niraparib, the GSK small-molecule inhibitor of poly-(ADP-ribose) polymerase (PARP).
Can you provide the latest stock price for IDEAYA BIOSCIENCES INC?
The current stock price of IDYA is 31.52 USD. The price decreased by -1.19% in the last trading session.
What is the dividend status of IDEAYA BIOSCIENCES INC?
IDYA does not pay a dividend.
What is the ChartMill technical and fundamental rating of IDYA stock?
IDYA has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What is the employee count for IDYA stock?
IDEAYA BIOSCIENCES INC (IDYA) currently has 131 employees.
What is the market capitalization of IDYA stock?
IDEAYA BIOSCIENCES INC (IDYA) has a market capitalization of 2.76B USD. This makes IDYA a Mid Cap stock.
When does IDEAYA BIOSCIENCES INC (IDYA) report earnings?
IDEAYA BIOSCIENCES INC (IDYA) will report earnings on 2026-05-04.